BioCryst reported a robust Q3 2025, driven by strong revenue growth for ORLADEYO, strategic divestitures, and a clean balance sheet, setting the stage for future expansion.

• ORLADEYO revenue guidance raised to $590-$600 million for 2025, even amid increased competition.
• Successful divestiture of European operations and debt payoff, resulting in an operating profit and positive cash flow.
• Encouraging early data expected from the BCX17725 study for Netherton syndrome, with patient enrollment slightly delayed.
• Anticipating the acquisition of Astria to enhance the pipeline with navenibart, targeting expanded HAE treatment options.
• New prescriptions for ORLADEYO exceeded prior year totals, reflecting continued strong market demand and physician trust.